Analyst consensus rating
Madrigal Pharmaceuticals Analyst Rating: Strong Buy
MDGL is rated Strong Buy by 16 analysts with a $678.06 target. As of 2026-08-24.
Direct answer
Madrigal Pharmaceuticals's consensus rating is Strong Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $678.06.
Forecast evidence checked August 24, 2026.
Get free Madrigal Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $516.74
- Average price target
- $678.06
- High price target
- $962.00
- Low price target
- $543.00
- Low target gap
- +5.1%
- Target upside
- +31.2%
- High target gap
- +86.2%
- Target range width
- 81.1%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $678.06.
How far are Madrigal Pharmaceuticals's low and high targets from the recorded price?
The low target implies +5.1%, while the high target implies +86.2%.
How many analysts are included in Madrigal Pharmaceuticals's consensus?
The verified consensus includes 16 analysts.
How is Madrigal Pharmaceuticals's target upside or downside calculated?
The average target of $678.06 is divided by the recorded price of $516.74, then one is subtracted to produce +31.2%. This does not guarantee a future return.
When was Madrigal Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.